India upholds basic patent on Tykerb; generics versions unlikely before 2019
This article was originally published in Scrip
Executive Summary
India's Intellectual Property Appellate Board (IPAB) has upheld the basic patent for GlaxoSmithKline's lapatinib compound, the active ingredient in the company's breast cancer drug Tykerb, keeping generic competition out of the market till at least 2019, unless a new legal challenge or a licensed second brand alters the scenario before that.